Quarterly report pursuant to Section 13 or 15(d)

Reverse Merger - Additional Information (Detail)

v3.10.0.1
Reverse Merger - Additional Information (Detail)
$ / shares in Units, $ in Millions
12 Months Ended
May 23, 2018
Aug. 01, 2017
Year
Right
$ / shares
shares
Jan. 05, 2017
Dec. 31, 2017
USD ($)
shares
Jun. 30, 2018
shares
Business Acquisition [Line Items]          
Reverse stock split ratio 0.1        
Common stock, shares outstanding | shares       1,194,793 4,238,526
Contingent value rights recovery | $       $ 0.2  
OncoGenex Pharmaceuticals, Inc [Member]          
Business Acquisition [Line Items]          
Reverse stock split ratio   0.0909 0.0909    
Share price | $ / shares   $ 46.20      
Common stock, shares outstanding | shares   273,670      
Number of non-transferable contingent value rights with potential cash and other consideration receivable right | Right   1      
OncoGenex Pharmaceuticals, Inc [Member] | Contingent Value Rights [Member]          
Business Acquisition [Line Items]          
Combined company acquisition period results   5 years      
Aggregate consideration distributed to the holders, consideration received percent   80.00%      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Price [Member] | Warrant [Member]          
Business Acquisition [Line Items]          
Fair value of outstanding warrants, assumptions   46.20      
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Fair value of outstanding warrants, assumptions   1.32      
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Fair value of outstanding warrants, assumptions   1.53      
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Fair value of outstanding warrants, assumptions   1 year 10 months 28 days      
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Fair value of outstanding warrants, assumptions   3 years 2 months 26 days      
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Fair value of outstanding warrants, assumptions   90.33      
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Fair value of outstanding warrants, assumptions   106.08      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Stock Price [Member]          
Business Acquisition [Line Items]          
Fair value of stock options, assumptions   46.20      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Fair value of stock options, assumptions   97.23      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Fair value of stock options, assumptions   106.63      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Fair value of stock options, assumptions   1.31      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Fair value of stock options, assumptions   1.54      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Minimum [Member]          
Business Acquisition [Line Items]          
Fair value of stock options, assumptions | Year   1.82      
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Maximum [Member]          
Business Acquisition [Line Items]          
Fair value of stock options, assumptions | Year   3.31